Table 6 Potential epigenetic drugs for the treatment of metabolic disease
From: Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study
Drugs | Target gene | Diseases | References |
|---|---|---|---|
DNMTi | |||
hydralazine | Nrf2 | diabetic nephropathy | |
procainamide | PDX1 | diabetes | |
decitabine | PPARγ | diabetes | |
5-aza-2’-deoxycytidine | PPARγ1 | obesity | |
5-aza-2’-deoxycytidine | PPAR-α | NAFLD | |
5-aza-2’-deoxycytidine | OPN, RUNX2 | diabetic osteoporosis | |
HDACi | |||
VPA | STAT5 | T1D | |
VPA | RUNX2 | osteoporosis | |
vorinostat | OPG | diabetes | |
vorinostat | EGFR | diabetic nephropathy | |
SAHA | Zfp719 | obesity | |
SAHA | insulin receptor β, Akt, and FoxO1 | osteoporosis | |
Givinostat | Gata3, FOXP3, IL-6, IL-12, TNF-α | diabetes | |
Givinostat | IL-1β, IL-6 and TNF-α | diabetes | |
Givinostat | IL-6, IL-1β, TNF-α | nonalcoholic steatohepatitis | |
Dacinostat | UCP1, Ppargc1α | obesity | |
TSA | AMPK | obesity | |
Puerarin | HDAC1/HDAC3 | diabetic osteoporosis | |
HATi | |||
Curcumin | FOXO1 | DCM | |
Curcumin | HSP-27, p38 | DN | |
C66 | CTGF, PAI-1 and FN-1 | DN | |
C646 | IRS1/2 | diabetes, obesity | |
STAC | |||
resveratrol | SIRT1, NF-kB-p65 | cardiac oxidative stress in diabetes | |
resveratrol | SIRT1, PGC-1α | Obesity, diabetic cardiomyopathy | |
resveratrol | SIRT1, FOXO3a | DN | |
resveratrol | SIRT1, FOXO 1 | osteoporosis | |
HPE | SIRT1, NF-kB, p53 | DN | |
ASO | |||
IONIS-GCGRRx | GCGR | T2D | |
Vupanorsen | ANGPTL3 | hepatic steatosis, diabetes | |
